AstraZeneca Acquires Amolyt Pharma with the Aim of Developing Rare Endocrine Disease Treatments

Acquisition is highlighted by eneboparatide, Amolyt’s Phase III peptide for hypoparathyroidism with a novel mechanism of action.

Source link
#AstraZeneca #Acquires #Amolyt #Pharma #Aim #Developing #Rare #Endocrine #Disease #Treatments